Skip to content
Evigrade
MinorVitamin D analogue (25-hydroxy metabolite)×Angiotensin-converting enzyme inhibitor (ACE-I)

Updated · Methodology

Mechanism

In the liver, ramipril is converted into active ramiprilat, and the metabolites are eliminated mainly by the kidneys. In renal impairment, ramiprilat is cleared more slowly and its levels rise (Acovil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the kidney and other tissues, the enzyme CYP27B1 converts calcifediol (25-hydroxyvitamin D3) into active calcitriol, CYP24A1 breaks both down into inactive metabolites, and calcifediol is excreted mainly in bile (Hidroferol SmPC, AEMPS; Rayaldee label, US Food and Drug Administration, FDA). The ramipril documents warn about substances that raise blood potassium or lower blood pressure, but the calcifediol documents do not place calcifediol in either group. The calcifediol interaction lists do not include angiotensin-converting enzyme (ACE) inhibitors (AEMPS and FDA documents for both).

Symptoms

The documents describe no symptoms linked to this combination. Ramipril can cause a marked fall in blood pressure, especially after the first dose or a dose increase. It can also raise blood potassium, worsen renal function and cause dry cough and angioedema (Acovil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; ramipril label, US Food and Drug Administration, FDA). Excess calcifediol causes hypercalcaemia with weakness, drowsiness, loss of appetite, nausea, vomiting, constipation, thirst and passing a lot of urine. Long-term excess can lead to calcium deposits in the kidneys and blood vessels (Hidroferol SmPC, AEMPS; Rayaldee label, FDA).

Management

According to the documents, the combination is acceptable, and the doses of ramipril and calcifediol need no change. No document names the pair, and neither drug belongs to the groups the other drug's documents warn about (Acovil and Hidroferol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; ramipril and Rayaldee labels, US Food and Drug Administration, FDA). Check renal function before starting ramipril and during treatment, especially in the first weeks, and monitor it very carefully in renal impairment (Acovil SmPC, AEMPS). In chronic kidney disease, monitor calcium and phosphate regularly during calcifediol treatment. With creatinine clearance below 30 mL/min, its effect may be much weaker (Hidroferol SmPC, AEMPS). In heart failure, which ramipril also treats, monitor blood calcium at all times during calcifediol treatment, especially in people taking cardiac glycosides. At the start of treatment, these tests are recommended twice a week (Hidroferol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Calcifediol (25-hydroxyvitamin D)